menu
    • menu

    Company profile for Skyline Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Skyline Therapeutics is a fully integrated gene and cell therapy company dedicated to the discovery, development, and delivery of innovative therapies. Through the development of transformative therapies, we are committed to making a meaningful impact on the lives of patients with devastating diseases. The Skyline team’s capabilities span capsid discovery, vector engineering and design, in-vivo pharmacology, clinical develop...
    Skyline Therapeutics is a fully integrated gene and cell therapy company dedicated to the discovery, development, and delivery of innovative therapies. Through the development of transformative therapies, we are committed to making a meaningful impact on the lives of patients with devastating diseases. The Skyline team’s capabilities span capsid discovery, vector engineering and design, in-vivo pharmacology, clinical development, analytical and process development, and CMC. Founded in 2019, Skyline Therapeutics is headquartered in China, with well-established research, development, and manufacturing capabilities in Shanghai and Hangzhou.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Skyline TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    2/F Building C, Jinke Center, No. 2727 Jinke Road, Zhangjiang Science City, Sh...
    Telephone
    Telephone
    +1 2120293666
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.skytx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/skytx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108
    Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108

    10 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyline-therapeutics-presents-late-breaking-abstract-on-skg1108-a-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025-302451661.html

    PR NEWSWIRE
    10 May 2025
    Share Share
    Skyline Therapeutics' SKG1108 Gene Therapy Receives FDA Orphan Status
    Skyline Therapeutics' SKG1108 Gene Therapy Receives FDA Orphan Status

    03 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyline-therapeutics-novel-gene-therapy-skg1108-receives-fda-orphan-drug-designation-for-retinitis-pigmentosa-302236346.html

    PR NEWSWIRE
    03 Sep 2024
    Share Share
    Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106
    Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106

    19 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyline-therapeutics-receives-china-nmpas-approval-of-ind-for-skg0106-a-novel-intravitreally-delivered-aav-gene-therapy-candidate-for-neovascular-age-related-macular-degeneration-301961848.html

    PR NEWSWIRE
    19 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search